Navidea Biopharma (NAVB) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Navidea Biopharma (NAVB) Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis
November 12, 2020 4:03 PM ESTNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from analysis of subjects who have completed Arm 3 of the Companys ongoing NAV3-31 Phase 2B study. These data further corroborate Navideas hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in patients with active rheumatoid arthritis (RA) and that this imaging can provide an early indicator of treatment efficacy.
Navideas NAV3-31 Phase 2B trial titled Evaluation of the Precision and Sensitivity of... More
